In Basic Science Commentary Noteworthy recent developments in stem cell biotechnology have opened up new possibilities for regenerating inhibitory synaptic connections within the damaged areas of the brain. In severe temporal lobe epilepsy (TLE), repeated seizures are thought to cause hippocampal sclerosis, often associated with loss or dysfunction of GABAergic interneurons. Several sources of GABAergic interneurons for cell replacement include neural progenitors from fetal brain tissue, embryonic stem cells (ESCs), and induced pluripotent stem cell (iPSCs). Progenitors harvested from the medial ganglionic eminence (MGE), a small region of the embryonic forebrain that produces specific subtypes of cortical and hippocampal GABAergic interneurons, differentiate into mature GABAergic interneurons and suppress seizures after engraftment into the adult rodent hippocampus (1, 2), providing proof-of-principle in the mouse pilocarpine model that GABAergic interneuron engraftment may be a promising treatment for severe TLE. These and many other studies have helped to define some of the parameters for fetal stem cell-based treatments for seizure disorders, one of the major goals in this field. However, an alternative stem cell source may be required moving into the clinic, as the ethical problems associated with obtaining large quantities of fetal human MGE cells make them unlikely cell sources for treating patients. Human iPSCs are one alternative cell source; they can be generated from a patient's own fibroblasts and are thus immu